Jennison Associates
RARE icon

Jennison Associates’s Ultragenyx Pharmaceutical RARE Stock Holding History

Jennison Associates’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-100,000
Closed -$9.63M – 728
2015
Q3 		$9.63M Buy
+100,000
New +$11.4M 0.01% 512

Other funds holding RARE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Jennison Associates's RARE Position: Q4 2017 in Review

Jennison Associates sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2017, closing a stake of 338,509 shares — an estimated $18M sold.

Jennison Associates first reported a position in RARE in Q1 2014 and held it in 15 quarters. The position peaked at $84.7M in Q4 2015. 163 funds tracked by Wall St. Rank hold RARE as of Q4 2017.

  • Jennison Associates reported no remaining Ultragenyx Pharmaceutical position as of Q4 2017 after selling out during the quarter.
  • Jennison Associates sold 338,509 Ultragenyx Pharmaceutical shares in Q4 2017, an estimated $18M.
  • Jennison Associates first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and held it in 15 quarters.
  • Jennison Associates's Ultragenyx Pharmaceutical position peaked at $84.7M in Q4 2015.
  • 163 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2017.

Based on Jennison Associates's 13F filing for Q4 2017, filed 25 Jan 2018.